D Aletaha

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Curr Rheumatol Rep 5:409-12. 2003
  2. pmc Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
    Daniel Aletaha
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 7:R796-806. 2005
  3. pmc Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind?
    Daniel Aletaha
    National Institutes of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Arthritis Res Ther 8:102. 2006
  4. ncbi request reprint Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease
    K P Machold
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Rheumatology (Oxford) 46:342-9. 2007
  5. pmc Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure
    Theresa Kapral
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 8:R46. 2006
  6. pmc Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials
    D Aletaha
    Intramural Research Program, NIAMS, National Institutes of Health, Bethesda, MD 20892, USA
    Ann Rheum Dis 65:227-33. 2006
  7. doi request reprint Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
    J S Smolen
    Department of Internal Medicine III, Medical University of Vienna, Austria
    Ann Rheum Dis 68:823-7. 2009
  8. doi request reprint Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    D Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 59:1371-7. 2008
  9. doi request reprint Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis
    T Karonitsch
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 67:1365-73. 2008
  10. pmc Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study
    M Schoels
    Second Department of Medicine, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 66:1059-65. 2007

Detail Information

Publications65

  1. ncbi request reprint Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: new aspects after the fall of the pyramid and the rise of new therapeutics
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Curr Rheumatol Rep 5:409-12. 2003
  2. pmc Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score
    Daniel Aletaha
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 7:R796-806. 2005
    ..e. the sum of tender and swollen joint counts [28 joints] and patient and physician global assessments [in cm]) - would have comparable validity in clinical cohorts...
  3. pmc Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind?
    Daniel Aletaha
    National Institutes of Arthritis, Musculoskeletal, and Skin Diseases, National Institutes of Health, Bethesda, Maryland, USA
    Arthritis Res Ther 8:102. 2006
    ..The choice of index in clinical practice should ideally be based on practical considerations related to the needs of the rheumatologist in the respective health care setting...
  4. ncbi request reprint Very recent onset rheumatoid arthritis: clinical and serological patient characteristics associated with radiographic progression over the first years of disease
    K P Machold
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Rheumatology (Oxford) 46:342-9. 2007
    ..This study was performed to determine the frequency of erosive arthritis and the pace of radiological progression in an inception cohort of patients with very early RA (<or=3 months after onset of symptoms)...
  5. pmc Methotrexate in rheumatoid arthritis is frequently effective, even if re-employed after a previous failure
    Theresa Kapral
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Arthritis Res Ther 8:R46. 2006
    ..Re-employment of MTX despite prior inefficacy, but not re-employment of other DMARDs, is an effective therapeutic option, especially in those patients in whom the methotrexate dose of the original course was low...
  6. pmc Duration of rheumatoid arthritis influences the degree of functional improvement in clinical trials
    D Aletaha
    Intramural Research Program, NIAMS, National Institutes of Health, Bethesda, MD 20892, USA
    Ann Rheum Dis 65:227-33. 2006
    ..Functional limitation incorporates both activity and damage. Because irreversible damage increases over time, the HAQ may be less likely to show improvement in late than in early rheumatoid arthritis...
  7. doi request reprint Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade
    J S Smolen
    Department of Internal Medicine III, Medical University of Vienna, Austria
    Ann Rheum Dis 68:823-7. 2009
    ..To examine the association of radiographic progression and disease activity states in patients with rheumatoid arthritis (RA) treated with methotrexate with or without infliximab...
  8. doi request reprint Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    D Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 59:1371-7. 2008
    ..To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)...
  9. doi request reprint Methods of deriving EULAR/ACR recommendations on reporting disease activity in clinical trials of patients with rheumatoid arthritis
    T Karonitsch
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 67:1365-73. 2008
    ....
  10. pmc Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study
    M Schoels
    Second Department of Medicine, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 66:1059-65. 2007
    ..In rheumatoid arthritis (RA), treatment with disease-modifying antirheumatic drugs (DMARDs) frequently needs to be changed because of insufficient effectiveness...
  11. pmc Perception of improvement in patients with rheumatoid arthritis varies with disease activity levels at baseline
    D Aletaha
    Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 61:313-20. 2009
    ..To analyze the minimum clinically important improvement (MCII) of disease activity measures in rheumatoid arthritis (RA) using patient-derived anchors, and to assess whether criteria for improvement differ with baseline disease activity...
  12. ncbi request reprint What should be our treatment goal in rheumatoid arthritis today?
    J S Smolen
    Department of Rheumatology, Medical University of Vienna Second Department of Medicine, Lainz Hospital, Vienna, Austria
    Clin Exp Rheumatol 24:S-7-13. 2006
    ....
  13. ncbi request reprint Assessing remission in clinical practice
    M Mierau
    2nd Department of Medicine, Hietzing Hospital, Vienna, Austria
    Rheumatology (Oxford) 46:975-9. 2007
    ..We aimed at evaluating sustained remission in a large cohort of patients followed prospectively in clinical practice and to evaluate available instruments to define remission for their stringency in defining this state...
  14. ncbi request reprint The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey
    D Aletaha
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Rheumatology (Oxford) 45:1133-9. 2006
    ..To investigate the perception of values of individual core set measures by rheumatologists, and how it differs across measures and across physicians...
  15. doi request reprint Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment
    D Aletaha
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 60:1242-9. 2009
    ..The aim of this study was to evaluate whether there is a latency in the effect of disease activity on radiographic progression in patients with RA...
  16. ncbi request reprint The use of databases for quality assessment in rheumatoid arthritis
    T A Stamm
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Clin Exp Rheumatol 25:82-5. 2007
    ....
  17. ncbi request reprint Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results
    D Aletaha
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
    Ann Rheum Dis 67:238-43. 2008
    ....
  18. doi request reprint Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing
    J S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090, Vienna, Austria
    Ann Rheum Dis 68:1535-40. 2009
    ....
  19. ncbi request reprint The burden of rheumatoid arthritis and access to treatment: a medical overview
    J Smolen
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Eur J Health Econ 8:S39-47. 2008
    ..Therapeutic outcome can be predicted by clinical means...
  20. ncbi request reprint Remission of rheumatoid arthritis: should we care about definitions?
    D Aletaha
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Clin Exp Rheumatol 24:S-45-51. 2006
    ..All composite indices seem to perform similarly well as tests for remission using expert judgments as the gold standard...
  21. doi request reprint Reporting disease activity in clinical trials of patients with rheumatoid arthritis: EULAR/ACR collaborative recommendations
    D Aletaha
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Ann Rheum Dis 67:1360-4. 2008
    ..To make recommendations on how to report disease activity in clinical trials of rheumatoid arthritis (RA) endorsed by the European League Against Rheumatism (EULAR) and the American College of Rheumatology (ACR)...
  22. ncbi request reprint Glucocorticoid treatment in rheumatoid arthritis: low-dose therapy does not reduce responsiveness to higher doses
    J Wolf
    Second Department of Medicine, Hietzing Hospital, Vienna, Austria
    Clin Exp Rheumatol 26:113-6. 2008
    ..Since low dose GC has been suggested to confer resistance to higher doses, we aimed to assess if resistance was detectable on the clinical level in patients with active RA...
  23. doi request reprint Does damage cause inflammation? Revisiting the link between joint damage and inflammation
    J S Smolen
    Division of Rheumatology, Department of Internal Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 68:159-62. 2009
    ..However, the clinical evidence for this relationship is still to be provided as proof of the concept...
  24. ncbi request reprint The rheumatoid arthritis patient in the clinic: comparing more than 1,300 consecutive DMARD courses
    D Aletaha
    Division of Rheumatology, Department of Internal Medicine III, University of Vienna, Vienna, Austria
    Rheumatology (Oxford) 41:1367-74. 2002
    ..This study aimed to reveal treatment patterns with traditional DMARDs and their changes during the two decades before the recent introduction of new DMARDs...
  25. ncbi request reprint The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis
    D Aletaha
    Department of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Clin Exp Rheumatol 23:S100-8. 2005
    ....
  26. ncbi request reprint Cytogenetic risk groups in acute myeloblastic leukaemia differ greatly in their semi-solid colony growth
    L Ohler
    Department of Internal Medicine I, University of Vienna, Vienna, Austria
    Br J Haematol 113:120-5. 2001
    ..0004). Our data suggest that the growth potential of the leukaemic clone seems to be critically influenced by the molecular changes emerging from chromosomal abnormalities...
  27. doi request reprint 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative
    Daniel Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 62:2569-81. 2010
    ..This work was undertaken to develop new classification criteria for RA...
  28. doi request reprint The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I
    Julia Funovits
    Division of Rheumatology, Medical University Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:1589-95. 2010
    ....
  29. doi request reprint The importance of reporting disease activity states in rheumatoid arthritis clinical trials
    Daniel Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 58:2622-31. 2008
    ..g., American College of Rheumatology [ACR] responder status) with the value of evaluating absolute disease activity states (e.g., remission)...
  30. pmc The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 10:208. 2008
    ..The analysis suggests the search for better markers to predict outcomes and therapeutic responsiveness in rheumatoid arthritis needs to be intensified...
  31. ncbi request reprint The need for new classification criteria for rheumatoid arthritis
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Rheum 52:3333-6. 2005
  32. pmc Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy
    Johannes Grisar
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 66:1284-8. 2007
    ....
  33. ncbi request reprint Therapeutic strategies in early rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Best Pract Res Clin Rheumatol 19:163-77. 2005
    ..Whether a 'window of opportunity' exists during which effective therapy might lead to cure is still an open issue and will be the focus of clinical trials in the near future...
  34. pmc Developments in the clinical understanding of rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, and 2nd Department of Medicine, Hietzing Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Arthritis Res Ther 11:204. 2009
    ..Finally, with the advent of novel therapies, remission has become a reality and the treatment algorithms encompassing all of the above-mentioned aspects will allow us to achieve the rigorous aspirations of today and tomorrow...
  35. doi request reprint The use of data from early arthritis clinics for clinical research
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine 3, Medical University of Vienna, Vienna, Austria
    Best Pract Res Clin Rheumatol 23:117-23. 2009
    ....
  36. ncbi request reprint The challenge of following process, damage, and function in patients with rheumatoid arthritis in clinical care
    Josef S Smolen
    Department of Rheumatology, Internal Medicine III, Vienna General Hospital, University of Vienna, Wolkersbergenstrasse 1, Vienna A 1130, Austria
    Curr Rheumatol Rep 5:336-40. 2003
  37. doi request reprint Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008
    Monika Schoels
    2nd Department of Medicine, Centre for Rheumatic Diseases, Hietzing Hospital, Vienna, Austria
    Ann Rheum Dis 69:575-8. 2010
    ..The importance of tight control and early treatment, rapidly altered if goals are not achieved, is supported by evidence. However, it is unknown to what extent these insights are accepted by practitioners in clinical practice...
  38. doi request reprint Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna General Hospital, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:1058-64. 2010
    ..Joint damage is an important outcome in trials of rheumatoid arthritis (RA), usually assessed by Total Sharp Score (TSS). It is currently unknown how it translates numerically into disability by the Health Assessment Questionnaire (HAQ)...
  39. ncbi request reprint New therapies for treatment of rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Lancet 370:1861-74. 2007
    ..Novel therapeutic strategies in conjunction with optimised disease assessment for better treatment of rheumatoid arthritis and an outlook into potential future targets are also presented...
  40. doi request reprint Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients
    Marcus D Köller
    Department of Rheumatology Internal Medicine III, General Hospital Medical University of Vienna, Vienna, Austria
    Rheumatology (Oxford) 48:1575-80. 2009
    ..To compare the efficacy of MTX and MTX+TNF inhibitors (TNFis) in elderly patients with RA with that in patients of younger age...
  41. doi request reprint The Simplified Disease Activity Index and Clinical Disease Activity Index to monitor patients in standard clinical care
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Rheum Dis Clin North Am 35:759-72, viii. 2009
    ..Moreover, remission criteria of CDAI and SDAI are currently the most stringent...
  42. pmc Treating rheumatoid arthritis to target: recommendations of an international task force
    Josef S Smolen
    Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:631-7. 2010
    ..Aiming at therapeutic targets has reduced the risk of organ failure in many diseases such as diabetes or hypertension. Such targets have not been defined for rheumatoid arthritis (RA)...
  43. pmc Evidence for treating rheumatoid arthritis to target: results of a systematic literature search
    Monika Schoels
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, Vienna, Austria
    Ann Rheum Dis 69:638-43. 2010
    ..To summarise existing evidence on a target oriented approach for rheumatoid arthritis (RA) treatment...
  44. pmc EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs
    Josef S Smolen
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:964-75. 2010
    ....
  45. ncbi request reprint The assessment of disease activity in rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, and Hietzing Hospital, Vienna, Austria
    Clin Exp Rheumatol 28:S18-27. 2010
    ..The latest developments in the field are discussed and will help to identify patients who can benefit most from today's opportunities of pharmacotherapy, allowing optimization of patient care...
  46. ncbi request reprint Laboratory testing in rheumatoid arthritis patients taking disease-modifying antirheumatic drugs: clinical evaluation and cost analysis
    Daniel Aletaha
    University of Vienna, Vienna, Austria
    Arthritis Rheum 47:181-8. 2002
    ..To develop and validate evidence-based recommendations for routine laboratory tests in patients with rheumatoid arthritis (RA) receiving traditional disease-modifying antirheumatic drugs (DMARDs), and to calculate the monitoring costs...
  47. ncbi request reprint Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis
    Johannes Grisar
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Circulation 111:204-11. 2005
    ..Because the quantity of endothelial progenitor cells (EPCs) in the peripheral blood is correlated inversely with cardiovascular risk, we studied whether such abnormalities could also be observed in patients with RA...
  48. ncbi request reprint Pro-inflammatory cytokines in rheumatoid arthritis: pathogenetic and therapeutic aspects
    Josef S Smolen
    Division of Rheumatology, Internal Medicine III, Medical University of Vienna, Austria
    Clin Rev Allergy Immunol 28:239-48. 2005
    ....
  49. ncbi request reprint Remission and active disease in rheumatoid arthritis: defining criteria for disease activity states
    Daniel Aletaha
    Department of Rheumatology, Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 52:2625-36. 2005
    ..We aimed to reevaluate or to define such criteria for the Disease Activity Score in 28 joints (DAS28) and the Simplified Disease Activity Index (SDAI)...
  50. ncbi request reprint The health assessment questionnaire in routine clinical practice
    Daniel Aletaha
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Nat Clin Pract Rheumatol 3:122-3. 2007
  51. ncbi request reprint Power Doppler sonography and pulse-inversion harmonic imaging in evaluation of rheumatoid arthritis synovitis
    Claudia Schueller-Weidekamm
    Department of Diagnostic Radiology, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    AJR Am J Roentgenol 188:504-8. 2007
    ....
  52. ncbi request reprint Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components
    Daniel Aletaha
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA
    Arthritis Rheum 54:2784-92. 2006
    ..We aimed to dissect these two components of functional limitation in rheumatoid arthritis (RA) by using the disability index of the Health Assessment Questionnaire (HAQ) as the measure of function...
  53. ncbi request reprint Challenges of predicting treatment response in patients with rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Nat Clin Pract Rheumatol 1:62-3. 2005
  54. pmc Remission by composite scores in rheumatoid arthritis: are ankles and feet important?
    Theresa Kapral
    Department of Rheumatology, Medical University of Vienna, Waehringer Guertel 18 20, 1090 Vienna, Austria
    Arthritis Res Ther 9:R72. 2007
    ..However, reduced joint counts are appropriate and valid tools for formal disease activity assessment, such as done in composite indices...
  55. ncbi request reprint The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care
    Daniel Aletaha
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Best Pract Res Clin Rheumatol 21:663-75. 2007
    ....
  56. ncbi request reprint Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients
    Daniel Aletaha
    Medical University of Vienna, Vienna, Austria
    Arthritis Rheum 56:3226-35. 2007
    ..To assess whether disease activity levels at treatment initiation or during the first 3 months of therapy predict disease activity at 1 year after treatment initiation...
  57. ncbi request reprint Early rheumatoid arthritis
    Klaus P Machold
    Department of Rheumatology, Internal Medicine III, Vienna Medical University, Austria
    Curr Opin Rheumatol 18:282-8. 2006
    ..This review provides novel and updated information on pathogenesis, referral, and clinical characteristics as well as therapeutic approaches in early rheumatoid arthritis...
  58. ncbi request reprint The definition and measurement of disease modification in inflammatory rheumatic diseases
    Daniel Aletaha
    Department of Rheumatology, Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Rheum Dis Clin North Am 32:9-44, vii. 2006
    ....
  59. doi request reprint Activity assessments in rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Austria
    Curr Opin Rheumatol 20:306-13. 2008
    ..the importance of assessing disease activity in general, aiming for significant improvement particularly low disease activity and remission, and the value of employing simplified instruments toward this end in rheumatoid arthritis..
  60. doi request reprint Strengths and limitations of a systematic review on DMARDs for rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Medical University of Vienna, Vienna, Austria
    Nat Clin Pract Rheumatol 4:296-7. 2008
  61. ncbi request reprint Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction?
    Josef S Smolen
    Medical University of Vienna and Lainz Hospital, Vienna, Austria
    Arthritis Rheum 52:2975-83. 2005
  62. doi request reprint Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis
    Valerie P Nell-Duxneuner
    Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Waehringer Guertel 18 20, A 1090 Vienna, Austria
    Ann Rheum Dis 69:546-9. 2010
    ..Specific composite indices assessing disease activity in psoriatic arthritis (PsA) have not yet been sufficiently validated. The objective of this study was to identify instruments best reflecting disease activity in PsA...
  63. ncbi request reprint Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study
    Daniel Aletaha
    Department of Internal Medicine, University of Vienna, Austria
    J Rheumatol 29:1631-8. 2002
    ..To determine the fate of traditional disease modifying antirheumatic drugs (DMARD) in the longer term, with special respect to dose related effects on drug retention rates, efficacy, and toxicity...
  64. ncbi request reprint The American College of Rheumatology N (ACR-N) debate: going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers
    Daniel Aletaha
    Arthritis Rheum 54:377-8; author reply 378. 2006
  65. ncbi request reprint Minimal disease activity for rheumatoid arthritis: a preliminary definition
    George A Wells
    Department of Epidemiology and Community Medicine, University of Ottawa, Ottawa, Ontario, Canada
    J Rheumatol 32:2016-24. 2005
    ..This set of 2 definitions gained approval of 73% of the attendees. These (and other) definitions will now be subject to further validation in other databases...